Navigation Links
UK is first to administer new anti-clotting technology

Volunteers at the Jack and Linda Gill Heart Institute at the University of Kentucky were the first ever to receive a new anti-clotting therapy. The drug and its antidote are being developed for their effectiveness in preventing blood clots while at the same time providing physicians the ability to rapidly reverse the effects of the blood thinner to help safeguard patients against uncontrolled bleeding.

More than 12 million patients are prescribed so-called "blood thinners" each year to prevent the formation of clots, which can block blood vessels, causing heart attacks, strokes and other debilitating or life-threatening conditions. Blood thinners, or antithrombotics, pose a risk of bleeding, particularly during surgery. The ability to stop the anti-clotting effects quickly could help protect patients from uncontrolled bleeding.

The Gill Heart Institute is one of two sites participating in the Phase 1 trial and is the first site to use the anti-clotting drug and its antidote.

This clinical trial will examine the drug's safety and tolerability in healthy volunteers as well as the antidote's ability to quickly reverse its effects. Although other new antithrombotics are undergoing testing in the U.S., this drug is believed to be the first of its kind.

"This class of drugs is a very promising technology that allows for the development of 'designer' drugs and their antidotes simultaneously," said Dr. Steven R. Steinhubl, the study's principal investigator at UK and director of cardiovascular education and clinical research at the Gill Heart Institute and a UK College of Medicine associate professor of cardiology. "It could have far-reaching implications."

"The research capacity of the cardiology division at UK has skyrocketed in the last year. Millions of dollars in research projects are under way, and we have attracted world-recognized leaders in drug discovery and development, such as Dr. Steinhubl. Leaders of technology and pharm aceutical companies have visited us in Lexington and are entrusting us to pioneer the next-generation of medicines and devices to improve healthcare," said Dr. David Moliterno, professor and vice chair of medicine, and chief, division of cardiovascular medicine, UK College of Medicine, and co-director of the UK Gill Heart Institute.

"Our goal is simple: we want to help patients with heart and vascular disorders by being at the forefront. Our research efforts are clearly bringing Kentuckians closer to the leading edge of the best medicine has to offer," Moliterno said.


'"/>

Source:University of Kentucky


Related biology news :

1. A genes first kiss sets off that affair known as puberty
2. Love at first smell
3. Worlds largest rainforest drying experiment completes first phase
4. PCRM develops worlds first cruelty-free insulin assay
5. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
6. World-first Living Donor Islet Cell Transplant A Success; Procedure Offers Promise For Diabetics
7. DuPonts first biologically derived polymer receives global recognition
8. Anti cancer virotherapy well tolerated in first human administration, research finds
9. Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development
10. The first impact factor for PLoS Biology ?13.9
11. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... WARSAW, Poland , Nov. 30, 2016 Not many of us realize ... crucial aspects of recovery so we need to do it well. Inadequate sleep levels ... problems, high blood pressure, stroke, diabetes, and even cancer. Maybe now is ... Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... BILLERICA, Massachusetts , 30. November 2016 ... und Technologieunternehmen, hat heute die Unterzeichnung einer ... gegeben. Diesen zufolge wird Evotec AG Screeningleistungen ... und shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese ... Bereich Screening eröffnet einen schnelleren Weg zur ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... for advanced technology applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, the ... Laser-Driven Light Source (LDLS™) technology, the EQ-77 offers higher radiance and irradiance from ...
Breaking Biology Technology: